Teplizumab: The Newest Weapon in the Fight against Type 1 Diabetes
DOI:
https://doi.org/10.61427/jcpr.v3.i2.2023.93Keywords:
Monoclonal Antibody, Teplizumab, Type-1 DiabetesAbstract
Teplizumab, a monoclonal antibody used for the prevention and treatment of type 1 diabetes, is the result of significant contributions from various scientists and researchers. This review explores the scientists' contributions and provides an overview of the drug's history and discovery. Teplizumab represents a significant advancement in the treatment of type-1 diabetes and holds promise for other autoimmune diseases. Its physicochemical properties, synthesis methods, therapeutic uses, and potential adverse effects contribute to its overall effectiveness and safety. Ongoing research and development aim to further enhance teplizumab's efficacy and convenience for patients.
Downloads
References
Kung PC, Goldstein G. Monoclonal antibodies. Proc Natl Acad Sci USA. 1979; 76(12): 5829-33.
Atkinson MA. The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med. 2012; 2(11): a007641.
Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010; 464(7293): 1293-1300.
Keymeulen B, Walter M, Mathieu C et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010; 53(4): 614-23.
Herold KC, Gitelman SE, Ehlers MR et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013; 62(11): 3766-74.
Herold KC, Bundy BN, Long SA et al. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019; 381(7): 603-613 doi:10.1056/NEJMoa1810911.
Sherry NA, Kushner JA, Glandt M et al. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 2006; 55(12):3238-45.
Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005 Oct; 115(10):2904-13. doi: 10.1172/JCI23961.
Ablamunits V, Bisikirska BC, Herold KC. Human regulatory CD8 T cells. Ann NY Acad Sci 2008; 1150: 234-8.
Provention Bio announces U.S. FDA grants Breakthrough Therapy Designation for Teplizumab for the delay or prevention of clinical type 1 diabetes. News release. PR Newswire. 2019.
Masharani UB, Becker J. Teplizumab therapy for type 1 diabetes. Expert Opin Biol Ther. 2010 Mar; 10(3):459-65. doi: 10.1517/14712591003598843.
Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in type 1 diabetes mellitus. ClinImmunol 2013; 149(3):268-78.
Hagopian W, Ferry RJ, Jr. Sherry N,et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: 2-year results from the randomized, placebo- controlled Protege trial. Diabetes 2013; 62(11): 3901-8.
Herold KC, Gitelman S, Greenbaum C et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. ClinImmunol 2009;132(2):166-73.
Sherry NA, Kushner JA, Glandt M. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 2006; 55(12):3238-45.
Ablamunits V, Bisikirska BC, Herold KC. Human regulatory CD8 T cells. Ann N Y Acad Sci. 2008 Dec;1150:234-8. doi: 10.1196/annals.1447.000.
Perdigoto AL, Hurlburt PP, Clark P, Long SA, Linsley PS, Harris KM, et al. Immune Tolerance Network. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia. 2019; 62(4):655-64. doi:10.1007/s00125-018-4489-6.
Teplizumab (Teplizumab-mzwv) [package insert]. Cambridge, MA: Provention Bio; 2022.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.